23. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, 3rd, Simons-Morton DG, Karanja N, Lin PH. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-sodium collaborative research group. *N Engl J Med*. 2001;344:3–10.
24. McKnight GM, Duncan CW, Leifert C, Golden MH. Dietary nitrate in man: Friend or foe? *Br J Nutr*. 1999;81:349–358.
25. L'hirondel J-L. *Nitrate and Man: Toxic, Harmless or Beneficial?* Wallingford, UK: CABI Publishing; 2001.
26. Hord NG, Tang Y, Bryan NS. Food sources of nitrates and nitrites: The physiologic context for potential health benefits. *Am J Clin Nutr*. 2009;90:1–10.
27. Larsen FJ, Ekblom B, Sahlin K, Lundberg JO, Weitzberg E. Effects of dietary nitrate on blood pressure in healthy volunteers. *N Engl J Med*. 2006;355:2792–2793.
28. Webb AJ, Patel N, Loukogeorgakis S, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. *Hypertension*. 2008;51:784–790.
29. Kapil V, Milsom AB, Okorie M, et al. Inorganic nitrate supplementation lowers blood pressure in humans: Role for nitrite-derived no. *Hypertension*. 2010;56:274–281.
30. Bryan NS, Fernandez BO, Bauer SM, et al. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. *Nat Chem Biol*. 2005;1:290–297.
31. Bryan NS, Calvert JW, Elrod JW, Gundewar S, Ji SY, Lefer DJ. Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. *Proc Natl Acad Sci U S A*. 2007;104:19144–19149.
32. Stokes KY, Dugas TR, Tang Y, Garg H, Guidry E, Bryan NS. Dietary nitrite prevents hypercholesterolemic microvascular inflammation and reverses endothelial dysfunction. *Am J Physiol Heart Circ Physiol*. 2009;296:H1281–1288.
33. Jadert C, Petersson J, Massena S, et al. Decreased leukocyte recruitment by inorganic nitrate and nitrite in microvascular inflammation and NSAID-induced intestinal injury. *Free Radic Biol Med*. 2012;52:683–692.
34. Sindler AL, Fleenor BS, Calvert JW, et al. Nitrite supplementation reverses vascular endothelial dysfunction and large elastic artery stiffness with aging. *Aging Cell*. 2011;10:429–437.
35. Carlstrom M, Persson AE, Larsson E, et al. Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension. *Cardiovasc Res*. 2011;89:574–585.
36. Montenegro MF, Amaral JH, Pinheiro LC, Sakamoto EK, Ferreira GC, Reis RI, Marcal DM, Pereira RP, Tanus-Santos JE. Sodium nitrite downregulates vascular nadph oxidase and exerts antihypertensive effects in hypertension. *Free Radic Biol Med*. 2011;51:144–152.
37. Montenegro MF, Pinheiro LC, Amaral JH, et al. Antihypertensive and antioxidant effects of a single daily dose of sodium nitrite in a model of renovascular hypertension. *Naunyn Schmiedebergs Arch Pharmacol*. 2012;385:509–517.
38. Carlstrom M, Larsen FJ, Nystrom T, et al. Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient mice. *Proc Natl Acad Sci U S A*. 2010
39. Duncan C, Dougall H, Johnston P, et al. Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate. *Nat Med*. 1995;1:546–551.
40. Bjorne HH, Petersson J, Phillipson M, Weitzberg E, Holm L, Lundberg JO. Nitrite in saliva increases gastric mucosal blood flow and mucus thickness. *J Clin Invest*. 2004;113:106–114.
41. Tsuchiya K, Kanematsu Y, Yoshizumi M, et al. Nitrite is an alternative source of NO in vivo. *Am J Physiol Heart Circ Physiol*. 2005;288:H2163–2170.
42. Cordain L, Eaton SB, Sebastian A, et al. Origins and evolution of the western diet: Health implications for the 21st century. *Am J Clin Nutr*. 2005;81:341–354.
43. Lundberg JO, Govoni M. Inorganic nitrate is a possible source for systemic generation of nitric oxide. *Free Radic Biol Med*. 2004;37:395–400.
44. Spiegelhalder B, Eisenbrand G, Preussmann R. Influence of dietary nitrate on nitrite content of human saliva: Possible relevance to in vivo formation of n-nitroso compounds. *Food Cosmet Toxicol*. 1976;14:545–548.
45 Lundberg JO, Weitzberg E, Cole JA, Benjamin N. Nitrate, bacteria and human health. *Nat Rev Microbiol*. 2004;2:593–602.
46. Lundberg JO, Weitzberg E, Lundberg JM, Alving K. Intragastric nitric oxide production in humans: Measurements in expelled air. *Gut*. 1994;35:1543–1546.
47. Benjamin N, O'Driscoll F, Dougall H, et al. Stomach NO synthesis. *Nature*. 1994;368:502.
48. Govoni M, Jansson EA, Weitzberg E, Lundberg JO. The increase in plasma nitrite after a dietary nitrate load is markedly attenuated by an antibacterial mouthwash. *Nitric Oxide*. 2008;19:333–337.
49. Petersson J, Carlstrom M, Schreiber O, et al. Gastroprotective and blood pressure lowering effects of dietary nitrate are abolished by an antiseptic mouthwash. *Free Radic Biol Med*. 2009;46:1068–1075.
50. Sobko T, Huang L, Midtvedt T, et al. Generation of NO by probiotic bacteria in the gastrointestinal tract. *Free Radic Biol Med*. 2006;41:985–991.
51. Bodner L. Effect of parotid submandibular and sublingual saliva on wound healing in rats. *Comp Biochem Physiol A Comp Physiol*. 1991;100:887–890.
52. Hart BL, Powell KL. Antibacterial properties of saliva: Role in maternal periparturient grooming and in licking wounds. *Physiol Behav*. 1990;48:383–386.
53. Benjamin N, Pattullo S, Weller R, Smith L, Ormerod A. Wound licking and nitric oxide. *Lancet*. 1997;349:1776.
54. Weller R, Price RJ, Ormerod AD, Benjamin N, Leifert C. Antimicrobial effect of acidified nitrite on dermatophyte fungi, candida and bacterial skin pathogens. *J Appl Microbiol*. 2001;90:648–652.
55. McKnight GM, Smith LM, Drummond RS, Duncan CW, Golden M, Benjamin N. Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans. *Gut*. 1997;40:211–214.
56. Duncan C, Li H, Dykhuizen R, et al. Protection against oral and gastrointestinal diseases: Importance of dietary nitrate intake, oral nitrate reduction and enterosalivary nitrate circulation. *Comp Biochem Physiol A Physiol*. 1997;118:939–948.
57. Dykhuizen RS, Frazer R, Duncan C, et al. Antimicrobial effect of acidified nitrite on gut pathogens: Importance of dietary nitrate in host defense. *Antimicrob Agents Chemother*. 1996;40:1422–1425.
58. Dykhuizen RS, Fraser A, McKenzie H, Golden M, Leifert C, Benjamin N. Helicobacter pylori is killed by nitrite under acidic conditions. *Gut*. 1998;42:334–337.
59. Dougall HT, Smith L, Duncan C, Benjamin N. The effect of amoxycillin on salivary nitrite concentrations: An important mechanism of adverse reactions? *Br J Clin Pharmacol*. 1995;39:460–462.
60. Wang CH, Ma MH, Chou HC, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: A systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med*. 2010;170:751–758.
61. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: Results from the women's health initiative. *Arch Intern Med*. 2010;170:765–771.
62. Lau YT, Ahmed NN. Fracture risk and bone mineral density reduction associated with proton pump inhibitors. *Pharmacotherapy*. 2012;32:67–79.
63. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. *Aliment Pharmacol Ther*. 2000;14:651–668.
64. Wimalawansa SJ. Nitric oxide and bone. *Ann N Y Acad Sci*. 2010;1192:391–403.
65. Jamal SA, Hamilton CJ, Eastell R, Cummings SR. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: A randomized trial. *JAMA*. 2011;305:800–807.
66. Jensen RT. Consequences of long-term proton pump blockade: Insights from studies of patients with gastrinomas. *Basic Clin Pharmacol Toxicol*. 2006;98:4–19.
67. Farooq M, Haq I, Qureshi AS. Cardiovascular risks of cox inhibition: Current perspectives. *Expert Opin Pharmacother*. 2008;9:1311–1319.
68. Yu Y, Ricciotti E, Scalia R, et al. Vascular cox-2 modulates blood pressure and thrombosis in mice. *Sci Transl Med*. 2012;4:132ra154.
69. Hart FD, Huskisson EC. Non-steroidal anti-inflammatory drugs. Current status and rational therapeutic use. *Drugs*. 1984;27:232–255.
70. Jansson EA, Petersson J, Reinders C, et al. Protection from nonsteroidal anti-inflammatory drug (nsaid)-induced gastric ulcers by dietary nitrate. *Free Radic Biol Med*. 2007;42:510–518.
71. Kevil CG, Kolluru GK, Pattillo CB, Giordano T. Inorganic nitrite therapy: Historical perspective and future directions. *Free Radic Biol Med*. 2011;51:576–593.
72. Bryan NS. Application of nitric oxide in drug discovery and development. *Expert Opin Drug Discov*. 2011;6:1139–1154.

Conflicts of Interest

N. S. Bryan has a financial interest in NeoGenis Inc. as a paid consultant and stock ownership. N. S. Bryan also has stock options in SAJE Pharma and has received honoraria for consulting services to Bristol Myers Squibb. His financial and research conflicts of interest are managed by UTHSCH Conflicts of Interest Management Plans, developed from and reviewed by the Research Conflicts of Interest Committee, and approved by the executive vice president for research at the University of Texas Health Science Center at Houston.

Nathan S. Bryan, PhD, is an assistant professor of molecular medicine within the Brown Foundation Institute of Molecular Medicine, part of the School of Medicine at the University of Texas Health Science Center at Houston. He is also on faculty within the Department of Integrative Biology and Pharmacology and Graduate School of Biomedical Sciences at the UT Houston Medical School. Dr. Bryan's research is dedicated to providing a better understanding of the interactions of nitric oxide and related metabolites with their different biological targets at the molecular and cellular level and the significance of these reactions for physiology and pathophysiology. Dr. Bryan has spent the past 12 years on research related to diagnosing NO insufficiency and natural strategies to restore NO production in the human body. These fundamental discoveries may provide the basis for new preventive or therapeutic strategies in diseases associated with NO insufficiency and new guidelines for optimal health. Dr. Bryan has published a number of highly cited papers and authored or edited 4 books.

Nathan S. Bryan, PhD
Assistant Professor of Molecular Medicine
Texas Therapeutics Institute
Brown Foundation Institute of Molecular Medicine, Department of Integrative Biology and Pharmacology
University of Texas Graduate School of Biomedical Sciences at Houston
University of Texas – Houston Health Science Center
1825 Pressler St. 530C
Houston, Texas 77030
713-500-2439 office
713-500-2447 fax
Nathan.Bryan@uth.tmc.edu
http://www.uthouston.edu/imm